Paratek Pharmaceuticals, Inc., a biopharma company focused on the development of therapies based on tetracycline chemistry, has opened a new office near Philadelphia in King of Prussia, PA.   Paratek, headquartered in Boston, currently employs 11 people in the Philadelphia area and expects to add more in the next year as it advances its lead clinical product candidate, omadacycline, a new once-daily oral and intravenous, broad-spectrum antibiotic for use as empiric monotherapy for serious commun...